Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 randomized double-blind vehicle-controlled study of topical INM-755 cream in healthy volunteers
NL-OMON48156Phase 1Completed
- Sponsor
- InMed Pharmaceuticals Inc.
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cannabinol topical in epidermolysis bullosa (EB) (4 arms), sponsored by InMed Pharmaceuticals Inc. Primary endpoints: Incidence of local and systemic treatment-emergent adverse events, Changes in vital signs, ECG, safety laboratory tests, erythema, and local tolerability assessment and 2 more. Started Dec 2019; status: completed.
02
Drugs
cannabinol topical
03
Conditions
epidermolysis bullosa (EB)
Beyond the preview
Go deeper on NL-OMON48156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48156.